Press release on Financial Results for the Half Year and Year ended on 31st March, 2026.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Aptus Pharma Limited, a BSE SME listed pharmaceutical company, reported strong financial results for FY26 with total revenue doubling to Rs. 4,670.81 lakhs from Rs. 2,463.64 lakhs in FY25, representing a 89.59% year-on-year growth. Net profit (PAT) increased by 49.05% to Rs. 461.99 lakhs. However, profitability margins compressed, with EBITDA margin declining from 19.31% to 16.06% and PAT margin falling from 12.58% to 9.89%, likely due to aggressive expansion costs. The company operates an asset-light model through WHO-GMP certified partners and has expanded its product portfolio to 250+ formulations across chronic, acute, and wellness segments. The business is structured across four verticals: Rx (prescription), OTC, Global exports, and ORBIT (franchise-led model), serving 25,000+ retail outlets through 200+ distributors and 10,000+ doctors.
The near-doubling of revenue demonstrates strong execution and market traction, but margin compression may concern investors focused on profitability quality. The company's expansion strategy and ambitious 2030 roadmap position it as a growing regional player, though investors should monitor whether margin recovery occurs as scale benefits kick in.